Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.34 USD | +1.51% | -2.93% | +58.33% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 800K | Capitalization | 646M |
---|---|---|---|---|---|
Net income 2024 * | -158M | Net income 2025 * | -241M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 808 x |
P/E ratio 2024 * |
-4.25
x | P/E ratio 2025 * |
-2.89
x | Employees | 157 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.3% |
Latest transcript on iTeos Therapeutics, Inc.
1 day | +1.51% | ||
1 week | -2.93% | ||
Current month | +61.43% | ||
1 month | +60.83% | ||
3 months | +61.88% | ||
6 months | +78.74% | ||
Current year | +58.33% |
Managers | Title | Age | Since |
---|---|---|---|
Michel Detheux
FOU | Founder | 57 | 12-03-31 |
Matthew Gall
DFI | Director of Finance/CFO | 47 | 20-05-31 |
Yvonne McGrath
CTO | Chief Tech/Sci/R&D Officer | 50 | 20-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ann Rhoads
BRD | Director/Board Member | 58 | 20-05-31 |
David Hallal
CHM | Chairman | 56 | 18-05-31 |
Director/Board Member | 52 | 18-05-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.13% | 28 M€ | -3.09% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-29 | 17.34 | +1.52% | 222,181 |
24-05-28 | 17.08 | -3.39% | 525,910 |
24-05-24 | 17.68 | +0.80% | 455,763 |
24-05-23 | 17.54 | -1.79% | 388,984 |
24-05-22 | 17.86 | -0.94% | 321,431 |
Delayed Quote Nasdaq, May 29, 2024 at 03:59 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+58.33% | 646M | |
+8.38% | 114B | |
+10.13% | 104B | |
-11.69% | 22.5B | |
+0.84% | 22.57B | |
-11.14% | 17.95B | |
-41.90% | 16.48B | |
-16.00% | 15.82B | |
+2.28% | 13.55B | |
+20.54% | 10.99B |
- Stock Market
- Equities
- ITOS Stock